Your Cart
Choose the formula built for what you want to support.
Choose Your SystemA real senior-dog randomized trial makes NAD+ and senolytics more serious than ordinary supplement buzzwords. It also sets hard limits: the study tested LY-D6/2, owner-assessed cognition, and a specific protocol - not every NAD+ product on the shelf.
It tested LY-D6/2, a specific senolytic and NAD+ precursor combination, in senior dogs with mild to moderate cognitive impairment.
The clearest signal was owner-assessed cognition using CCDR score change at the 3-month endpoint.
In-house cognitive testing and measured physical activity did not show significant between-group differences.
No. The result belongs to a specific combination, dose design, population, and endpoints.
Use it to demand specificity: active disclosure, pathway explanation, outcome limits, and no dog-dementia treatment language.
Seventy senior dogs with mild to moderate cognitive impairment were randomized to placebo, low-dose, or full-dose LY-D6/2. Owner-reported CCDR score change differed at 3 months, with the largest decrease in the full-dose group. Activity monitors and in-house cognitive testing did not show clear between-group differences.
This is meaningful geroscience evidence. That makes restraint more important, not less: the trial supports a specific combination and endpoint pattern, not generic NAD+ product claims.
This was not a generic NAD+ paper. It was a senior-dog clinical trial of a specific combination.
The enrolled dogs had mild to moderate cognitive impairment and were randomized to placebo, low-dose, or full-dose LY-D6/2. The intervention included a novel NAD+ precursor and a senolytic, so the study should be read as combination geroscience rather than as proof for any single ingredient.
The primary window was 3 months, with additional 6-month follow-up. That is practical for shoppers: long enough for caregivers to notice patterns, not long enough for lifespan or long-term disease-modification claims.
The strongest positive result was caregiver-observed cognition.
The authors reported a significant difference in CCDR score change across groups from baseline to the 3-month endpoint, with the largest decrease in the full-dose group. They also noted broader but more subtle owner-reported patterns around frailty, activity, and happiness.
The restraint matters. No between-group difference was detected on in-house cognitive testing, and measured activity did not differ significantly. All groups improved on cognition, frailty, and activity measures, so trial attention and caregiver placebo effects cannot be ignored.
The paper does not turn NAD+ into a universal senior-dog answer.
The tested intervention was LY-D6/2, not "any NAD+ supplement." It was a combination product, not a single isolated nutrient. It studied owner-assessed cognition and related senior-dog measures, not lifespan.
The study is exciting because it is specific. Brands weaken it when they generalize it into generic NAD+ enthusiasm.
It moves pet geroscience from theory toward client-owned senior dogs.
That matters because many pet longevity claims lean on cell culture, rodent papers, or human data. Simon 2024 is closer to the animal and the buying decision.
It also teaches shoppers to read mixed endpoints. A useful paper can have a positive owner-assessed signal and still show no clear objective activity difference. That is not a failure; it is the texture of real clinical evidence.
Use this study as a filter, not as a checkout button.
A senior-dog product can responsibly support aging biology without pretending to be LY-D6/2.
The honest bridge is narrow: disclose the actives, explain the pathway, show testing and dose logic, and make the product easy to run as a clean daily trial.
Hollywood Elixir uses disclosed aging-biology support, including NAD+ and mitochondrial-relevant pathways. It is not LY-D6/2 and does not claim to reproduce this trial.
The easiest misuse is turning a specific combination trial into generic NAD+ proof.
Another misuse is turning owner-assessed improvement into disease-treatment language. A third is burying the null or mixed endpoints because they complicate the sales story.
The stronger commercial posture is more adult: this is promising senior-dog geroscience, and it raises the bar for disclosure and claim discipline.
A quick read on the claims a pet parent is likely to see while shopping.
"This proves NAD+ supplements improve dog cognition."
The study tested one combination, not the category.
Better: this specific trial supports serious interest in NAD+ plus senolytic geroscience.
Specificity protects the claim.
"It treats dog dementia."
The paper did not establish disease treatment and used mixed endpoint types.
Better: owner-assessed cognitive support signal in senior dogs.
This matches the endpoint without crossing the line.
"All endpoints improved."
Measured activity and in-house cognitive testing did not show clear between-group differences.
Better: the paper is promising and mixed.
Honest nuance builds authority.
Use this as a shopper decoder: the idea can be useful, but the claim still has to stay honest.
| Concept | Common claim | Better interpretation | Caution | LPL system |
|---|---|---|---|---|
| NAD+ pathway | "NAD+ proven for senior dog cognition." | Name the ingredient architecture and say which endpoint was measured. | Generic NAD+ transfer is too broad. | Hollywood Elixir |
| Senolytics | "Clears aging cells in dogs." | Frame as a studied combination in one trial; avoid mechanism certainty beyond the paper. | Do not imply a measured cell-clearance outcome if not shown. | Research Library |
| Cognition | "Treats canine cognitive dysfunction." | Support healthy cognitive aging and refer clinical signs to veterinary care. | Disease-treatment language is not supported. | LPL-01 |
| Clean trial | "You will see results." | Track specific daily signals for 60 days while keeping other variables stable. | Owner observation is useful but noisy. | COA Lookup |
Use these questions before accepting any study-backed product claim.
We read Simon 2024 as permission to be serious about geroscience, not permission to overclaim.
Hollywood Elixir is built around disclosed aging-biology support, including NAD+ and mitochondrial-relevant pathways. It is not LY-D6/2, and it does not claim to reproduce this trial.
The honest commercial bridge is narrower and stronger: senior-dog buyers should prefer products that disclose the pathway architecture, avoid disease-treatment language, and make a clean routine easy to track.
NAD+ language is only useful when the product discloses the actives, dose logic, pathway, and claim boundary.
Short answers for the shopping questions this study usually creates.
It tested LY-D6/2, a specific senolytic and NAD+ precursor combination, in senior dogs.
Owner-assessed cognition using CCDR score change showed the clearest signal at the 3-month endpoint.
In-house cognitive testing and measured activity did not show clear between-group differences.
No. The result belongs to the tested combination and protocol.
Look for disclosed actives, dose logic, pathway clarity, tracking guidance, and no disease-treatment language.
We use it as a geroscience and claim-boundary reference, not as proof that Hollywood Elixir reproduces LY-D6/2 outcomes.
Useful definitions for reading the study without turning it into marketing haze.
Primary paper first, followed by practical veterinary or nutrition references where relevant.
Research Library is educational. It does not diagnose, treat, cure, or prevent disease, and it does not replace veterinary advice.
